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Background: Edwards Sapien valve is usually implanted through either transfemoral
(TF) or transapical (TA) route. We evaluate feasibility and results of implantation of
Edwards Sapien valve through Transaortic (TAo) route in patients with aortic stenosis.
Methods: Between January 2008 and May 2011 a total of 560 patients underwent
TAVI using the Edwards Lifesciences SapienTM valve in our institutions, of which 58
patients (10.4%) underwent a TAo procedure using Ascendra delivery system. All
patients were discussed in a multidisciplinary meeting and the decision for TAVI was
based on high predictive risk for AVR. Patients with poor vascular access who were
considered unsuitable for TF approach were considered for TAo approach if TA
approach was either not feasible (3/58) or desirable due to poor lung function (19/58),
poor left ventricular function (6/58), fatty heart (2/58) and surgeons preference (28/58).
Seven of these patients had also undergone at least one previous heart operation
(12.1%).
Results: Mean age was 80 ±6.6y and 61% were female (n=23). Mean logistic
Euroscore was 32 ±16 and STS score 8.09 ±3. The mean ejection fraction was 45 ±16
%, valve area 0.6 ±0.2cm2 and peak gradient 67 ±19mmHg. All procedures were
performed under general anaesthesia. Valve sizes used were 23mm (n=27, 46%), 26mm
(n=29, 50%) and 29mm (n=2, 4%). Procedural success was achieved in all patients
(100%). Post procedural mean and peak gradients were 6.2 and 11mmHg respectively.
None of the patients had more than Grade 1 AR at discharge. None of the patients
suffered postoperative stroke or persistent AV block. Incidence of renal failure requiring
dialysis was 5.2% (3/58) and major vascular complication was <1% (1/58). The overall
30-day mortality was 7% (4/58).
Conclusion: Trans-aortic TAVI is a feasible and safe approach in the treatment of aortic
stenosis using Edwards Sapien valve and Ascendra delivery system with low in-
hospital complication rates. Despite high incidence of respiratory disease the outcome
in this subgroup of patients was satisfactory with excellent short-term results.
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Background: For patients with severe aortic stenosis at high risk for surgical
replacement, transcatheter aortic valve implantation (TAVI) is a therapeutic option. We
report twelve-month results from a multicenter study in Australia and New Zealand.
Methods: The CoreValve (Medtronic, Irvine, Calif.) Australia-New Zealand study is
a fully monitored study with independent adjudication of adverse events. The study
has enrolled 229 subjects at eight centers since 2008. Inclusion criteria included severe
symptomatic aortic valve disease, age >80 or >65 with 1-2 high-risk co-morbidities or
logistic EuroSCORE >20.
Results: Subjects were male 56%, age 84+6 years, logistic EuroSCORE 18+11, NYHA
class III/IV 80%. Procedural success (successful implant without conversion to surgery
or death) was 96.9%. Thirty-day all-cause mortality was 4.1% and the stroke rate was
1.9%. In 86 subjects after 12 months, all-cause survival was 88.0+4.5% and cardiac
survival was 92.2+3.8%. Valve orifice area and mean gradient showed statistical
improvements at 30 days and 12 months. No valve migrations or structural valve
deteriorations were reported. Aortic regurgitation grades at 12 months via echo were
<2 in 94.0% of patients. Most (76.7%) improved >1 NYHA class at 12 months and
only 3.3% worsened.
Conclusion: The 18Fr CoreValve TAVI prosthesis is safe and effective at twelve
months in this monitored and adjudicated multicenter trial. Stable mortality and
morbidity outcomes are within expectations for percutaneously treated subjects with
severe symptomatic aortic stenosis in this very high-risk subgroup. Enrollment and
long-term follow-up are ongoing and updated results, including vascular complications
and pacemaker implants, will be forthcoming.
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Background: Recently Transcatheter Aortic Valve Implantation (TAVI) using balloon-
expandable prostheses favorably compared to conservative management in inoperable
patients and to surgery in high-risk patients. However, no data in comparison with
surgery exists for self-expandable prostheses. We assessed prosthesis performance and
clinical outcome of TAVI using self-expandable or balloon-expandable devices.
Methods: Valve performance and outcome were assessed in a prospective registry
including all patients who underwent TAVI in our Department. The III generation
CoreValve Revalving System was implanted between June 2007 and March 2009
(CRS. Medtronic, Minneapolis, Minnesota USA) and the Edwards SAPIEN/SAPIEN
XT between April 2009 and May 2011 (ES. Edwards Lifesciences Irvine, CA, USA).
Safety and efficacy end-points were expressed according to VARC definitions.
Results: One-hundred and ninety-eight patients underwent TAVI, 87 (43.9%) with
CRS (82 transfemoral and 5 trans-subclavian), 111 (46.1%) with ES device (62
transapical and 49 transfemoral). Mean age was 81.0 ± 6.6 years (55.1% female),
logistic EuroSCORE of 21.4 ± 13.3%. Procedural success was 94.3% in CRS and
95.5% in ES (p= ns). Back-up strategies to achieve procedural success (re-dilatation,
valve snaring or valve-in-valve) was higher in CRS (p= 0.02). Thirty-day mortality
was 5.7% in CRS and 2.9% in ES (p= 0.32). Thirty-day combined safety end-point
(VARC) was 14.9% in CRS vs 19.2% in ES (p=0.43). AV-block requiring pacemaker
implantation were 40.7% in CRS, vs 8.6% in ES (p< 0.001). At follow-up (mean
12.4±9.7 months), 13.6% patients died, 4.0% had cardiovascular death, without
differences between groups. However, the combined efficacy endpoint (VARC) at 1-
year was 31.7% in CRS and 9.8% in ES (p=0.01). At both 48-h and follow-up
echocardiograms, effective orifice area was larger in CRS (p= 0.01), and moderate-to-
severe paravalvular leak was more frequent in CRS (p= 0.01).
Conclusion: TAVI using both self-expandable and balloon-expandable prostheses
seems a safe alternative to surgery in high-risk aortic stenosis. However, prosthesis
performance as well as 1-year effectiveness were higher using balloon-expandable
devices.
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Background: The reproducibility and applicability of multidetector computed
tomography (MdCT) annular measurements to guide transcatheteraortic valve
implantation (TAVI) remain unclear. Prior studies desmonstrated discordance between
echocardiography and MdCT, suggesting that MdCT guided valve implantation would
frequently alter the treatment strategy despite good results with echocardiographic
sizing.
Methods: Fifty patients underwent MdCT evaluation prior to possible TAVI. Annular
measurements were performed in blinded fashion by 3-independent readers in multiple
planes. A theoretical model was developed taking into account differences between the
most reproducible MdCT measurements and transesophageal echocardiography (TEE)
to guide valve size choice.
Results: The most reproducible MdCT measurements were the Area Derived Diameter
and Basal Ring Average Diameter [inter-reader correlation 0.87(95%C.I 0.81-0.92)
and 0.80 (95%C.I 0.70-0.87) respectively, intra-reader >0.90 for all readers]. These
measurements were larger than TEE diameters (mean difference 1.5±1.6mm and
1.1±1.7mm respectively). When a strategy of valve sizing based on MdCT
measurements but according to current TEE based cutoffs was used, a different valve
size was chosen in 44-40% respectively. When adjusting the sizing cutoffs to account
for the differences in observed diameters, this was reduced to 10-12% (p<0.01 for
both). In cases with persistent discrepancies, the incidence of significant aortic
incompetence was as high as 75%.
Conclusion: The most reproducible MdCT measurements of the annulus are the Area
Derived Diameter and Basal Ring Average Diameter, with values generally larger than
those obtained with echocardiography. If MdCT is used for valve sizing, a strategy
incorporating these differences appears to be important. MdCT may reduce the
incidence of inadvertent undersizing in selected cases.
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